Cyporin DS is the preparation of Cyclosporine 0.1%. Cyclosporine 0.1% is the 1st & only US-FDA approved topical immunomodulator for the treatment of VKC in children & adults.
Cyporin DS is the preparation of Cyclosporine 0.1%. Cyclosporine 0.1% is the 1st & only US-FDA approved topical immunomodulator for the treatment of VKC in children & adults. It is also suitable treatment option for severe keratitis in adult patients with dry eye disease which has not improved despite treatment with tear substitutes. According to study the sign & symptoms of VKC reduces as early as 1 month. Due to emulsion technology, it does not need to shake, so patients get the medicine uniformly.
For the 1st time in Bangladesh Cyporin DS, preparation of Cyclosporine 0.1% is manufactured from EU-GMP approved largest ophthalmic plant in Bangladesh, which ensures the optimum quality of the product.
Cyporin DS Ophthalmic Emulsion: Each ml contains Cyclosporine USP 1 mg.
Cyporin DS Ophthalmic Emulsion is indicated to treatment of vernal keratoconjunctivitis (VKC) in children and adults & severe keratitis in adult patients with dry eye disease which has not improved despite treatment with tear substitutes.
Cyporin DS Ophthalmic Emulsion: In case of VKC: Instill one drop 4 times daily (morning, noon, afternoon, and evening) in each affected eye(s). In case of Severe keratitis in adult patients with dry eye disease: Instill one drop once daily to be applied to the affected eye(s) at bedtime. Response to treatment should be reassessed at least every 6 months. Cyclosporine Ophthalmic Emulsion can be used concomitantly with artificial tears, allowing a 15-minutes interval between products.
Cyclosporine Ophthalmic Emulsion is contraindicated in patients with active ocular infections and in patients with known or suspected hypersensitivity to any of the ingredients in the formulation.
Cyclosporine Ophthalmic Emulsion should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to the administration of this formulation and lenses may be reinserted in 15 minutes following administration of Cyclosporine ophthalmic emulsion.
Overdose: A topical overdose is not likely to occur after ocular administration. If overdose with Cyclosporine occurs, treatment should be symptomatic and supportive.
The most common adverse event was ocular burning. Other events reported included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).
Pregnancy Use: There are no adequate and well-controlled studies of Cyclosporine Ophthalmic Emulsion in pregnant women. It should be administered to pregnant women if clearly needed. Lactating Women Use: Cyclosporine is known to be excreted in human milk following systemic administration but excretion in human milk after topical treatment has not been investigated. Paediatric Use: The safety and efficacy of Cyclosporine 0.05% Ophthalmic Emulsion have not been established in paediatric patients below the age of 16. But clinical study shows that Cyclosporine Ophthalmic Emulsion is safe for children above one year of age. The safety and efficacy of Cyclosporine 0.1% Ophthalmic Emulsion have not been established in paediatric patients below the age of 4 through 18 years of age.
Cyporin DS Ophthalmic Emulsion: Each LDPE dropper bottle contains 5 ml Sterile Eye Drops.
FR
DE